Hapke E

Psychiatrist, psychotherapist, and psychedelic researcher at the University Health Network in Toronto.

8 papers

ArticlePsychedelics

Psychedelic-assisted psychotherapy : Emerging paradigm

Shane D, Akhtar S, Hapke E

Europe PMC2026
ArticlePsilocybin

Psilocybin for Fear of Cancer Recurrence.

Cho M, Rosenbaum D, Hapke E +1

Europe PMC2026
ArticlePsilocybin

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial.

Richardson C, Chan C, Macgregor E +15

Europe PMC2025
ArticleMDMA

MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.

Mitchell JM, Bogenschutz M, Lilienstein A +35

Europe PMC2023
ArticlePsilocybin

Psilocybin mushrooms for psychological and existential distress: Treatment for a patient with palliative lung cancer.

Patchett-Marble R, O'Sullivan S, Tadwalkar S +1

Europe PMC2022
ArticlePsilocybin

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.

Rosenbaum D, Weissman C, Anderson T +4

Europe PMC2020
ArticlePsilocybin

Psychedelic microdosing benefits and challenges: an empirical codebook.

Anderson T, Petranker R, Christopher A +5

Europe PMC2019
ArticlePsilocybin

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.

Anderson T, Petranker R, Rosenbaum D +5

Europe PMC2019